Skip to content
Taxonomy
Can We Fix the Code? A Look at Genetic Therapies for CMT
By Katherine Forsey, PhD | CMTA Chief Research Officer Current Read More
What If We Could Measure CMT4J Getting Worse Before It Feels Worse?
Tracking CMT4J from the Inside Out: What MRI Scans Are Read More
CMTA-STAR Alliance Partner Begins Clinical Trial in CMT2S
CMTA Strategy To Accelerate Research (CMTA-STAR) Alliance Partner Vanda Pharmaceuticals Read More
What 50 People Taught Us About CMT1E Progression and Genetics
The Charcot-Marie-Tooth Association (CMTA), the world’s largest philanthropic funder of Read More
Augustine Therapeutics Begins New CMT Trial
CMT news out of Belgium: Augustine Therapeutics has officially dosed Read More
CMTA-STAR Partner Applied Therapeutics Presents 24-Month CMT-SORD Data at PNS 2025
The Charcot-Marie-Tooth Association (CMTA) congratulates CMTA Strategy To Accelerate Research Read More
CMTA Presents New Genetic Landscape Analysis at The 2025 Annual Meeting of the Peripheral Nerve Society
The Charcot-Marie-Tooth Association (CMTA), the largest philanthropic funder of Charcot-Marie-Tooth Read More
CMTA-INC Alliance Announces 2025 Inherited Neuropathies Fellowship Recipient
The Charcot-Marie-Tooth Association (CMTA), the largest philanthropic funder of Charcot-Marie-Tooth Read More
Could MRI Help Speed Up CMT1A Research? New Findings from Professor Mary M. Reilly, MBE
A newly published study led by CMTA’s Strategy to Accelerate Read More
CMTA Invests $210K in Long-Read Sequencing to Accelerate CMT Gene Discovery
Today, the Charcot-Marie-Tooth Association (CMTA) announced a $210,000 investment to Read More
